Fresenius Kabi Oncology Ltd

Fres.Kabi Onco. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Fresenius Kabi Oncology Ltd

₹ 132 0.34%
02 Jan 2014
Company website BSE: 532545
About

Fresenius Kabi Oncology Limited engages in the development, manufacture, and marketing of chemotherapeutic drugs for the treatment of cancer.

[ add key points ]
Website BSE
  • Market Cap ₹ Cr.
  • Current Price ₹ 132
  • High / Low ₹ /
  • Stock P/E
  • Book Value ₹ 25.7
  • Dividend Yield 0.00 %
  • ROCE 8.61 %
  • ROE 11.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 5.15 times its book value
  • The company has delivered a poor sales growth of 10.1% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 6.57% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Multinational

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Jun 2013 Sep 2013 Dec 2013
93 127 96 85
82 118 125 121
Operating Profit 11 8 -29 -37
OPM % 12% 7% -30% -43%
-6 1 0 -6
Interest -2 -5 7 10
Depreciation 7 7 8 8
Profit before tax 1 7 -44 -61
Tax % 962% 32% 2% 4%
-8 5 -45 -64
EPS in Rs -0.49 0.30 -2.83 -4.02
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2008 Mar 2009 Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
241 257 411 413 527 596 408 464 542 624 703 660
215 335 325 341 505 453 480 552 546 549 571 569
Operating Profit 26 -78 87 71 22 143 -72 -88 -5 75 132 90
OPM % 11% -30% 21% 17% 4% 24% -18% -19% -1% 12% 19% 14%
180 37 31 34 91 -5 -8 -34 -13 13 -13 -60
Interest 8 22 19 18 18 -3 13 -13 29 37 46 37
Depreciation 5 12 13 17 24 26 31 44 52 49 55 55
Profit before tax 192 -75 86 70 72 115 -123 -154 -99 2 18 -61
Tax % 22% 4% 7% 30% 29% 30% -10% 2% -17% 213% -6% -12%
149 -78 80 49 51 81 -111 -157 -83 -2 20 -54
EPS in Rs 9.53 -4.91 5.07 3.11 3.22 5.09 -7.04 -9.93 -5.22 -0.15 1.24 -3.41
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 10%
5 Years: 10%
3 Years: 7%
TTM: -6%
Compounded Profit Growth
10 Years: 10%
5 Years: 20%
3 Years: 42%
TTM: 15%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: %
Return on Equity
10 Years: 1%
5 Years: -4%
3 Years: 7%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2008 Mar 2009 Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Equity Capital 16 16 16 16 16 16 16 17 17 17 17 17
Reserves 483 396 476 526 577 657 546 505 424 421 441 390
195 242 269 333 147 140 311 349 421 521 474 463
108 120 150 185 181 226 226 245 317 260 298 360
Total Liabilities 802 774 912 1,059 921 1,039 1,098 1,116 1,179 1,219 1,231 1,229
74 196 195 258 305 352 463 483 522 494 469 456
CWIP 123 3 58 96 140 163 79 55 30 45 38 37
Investments 183 129 129 126 0 0 0 0 0 0 0 0
421 447 529 579 476 524 556 578 626 680 724 736
Total Assets 802 774 912 1,059 921 1,039 1,098 1,116 1,179 1,219 1,231 1,229

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2008 Mar 2009 Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
-65 -55 56 50 174 128 -53 -121 8 -39 112 98
19 30 -63 -116 17 -121 -86 -44 -40 -29 -30 -52
49 28 32 49 -196 -20 140 164 -48 147 -29 -10
Net Cash Flow 2 2 26 -16 -5 -13 1 -1 -79 79 53 36

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2008 Mar 2009 Mar 2010 Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Debtor Days 142 145 134 156 140 113 100 93 90 83 84 83
Inventory Days 466 679 584 559 317 543 662 452 581 579 510 523
Days Payable 264 235 221 219 159 202 380 261 298 233 219 301
Cash Conversion Cycle 344 589 497 496 298 454 382 283 372 430 375 305
Working Capital Days 453 462 307 337 206 193 292 261 221 258 233 213
ROCE % 34% -8% 13% 10% 6% 15% -11% -14% -5% 4% 11% 9%

Shareholding Pattern

Numbers in percentages

Shareholding pattern is currently not available for this company.

Documents

Announcements

All

No data available.

Annual reports